Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 12/20 | 0.77 |
| ▸ | THRB | P10828 | 12/20 | 0.77 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.65 |
| ▸ | RARB | P10826 | 5/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | RARA | P10276 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | MTOR | P42345 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15174539 | 1.00 | THRA (0.77) | THRATHRBHAO1RARBMEN1 | |
| SCHEMBL15186439 | 1.00 | THRA (0.77) | THRATHRBHAO1RARBMEN1 | |
| SCHEMBL8984157 | 1.00 | THRA (0.77) | THRATHRBHAO1RARBMEN1 | |
| SCHEMBL7736637 | 1.00 | THRA (0.77) | THRATHRBHAO1RARBMEN1 | |
| SCHEMBL8388153 | 1.00 | THRA (0.77) | THRATHRBHAO1RARBMEN1 | |
| SCHEMBL8984247 | 1.00 | THRA (0.77) | THRATHRBHAO1RARBMEN1 | |
| SCHEMBL638654 | 0.98 | THRA (0.73) | THRATHRBHAO1RARBMEN1 | |
| SCHEMBL11110027 | 0.95 | THRA (0.70) | THRATHRBHAO1RARBMEN1 | |
| SCHEMBL3011724 | 0.93 | THRA (0.66) | THRATHRBHAO1RARBALDH1A1 | |
| SCHEMBL8205823 | 0.88 | RARB (0.68) | THRATHRBHAO1RARBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1165563-A1 | BICYCLIC HETEROCYCLES, METHOD FOR PRODUCING THEM AND THEIR USE AS HERBICIDES AND PHARMACEUTICAL AGENTS | Aventis CropScience GmbH (DE) | 2002-01-02 | — | — | EP | claimed |
| WO-2000056734-A1 | BICYCLIC HETEROCYCLES, METHOD FOR PRODUCING THEM AND THEIR USE AS HERBICIDES AND PHARMACEUTICAL AGENTS | AVENTIS CROPSCIENCE GMBH (DE) | 2000-09-28 | — | — | WO | claimed |
| EP-2896609-B1 | Crystalline fingolimod citrate for the treatment of relapsing-remitting multiple sclerosis | RATIOPHARM GMBH (DE) | 2018-06-27 | — | — | EP | disclosed |
| EP-1457478-B1 | Production of 2-amino-2-[2-(4-alkyl-phenyl)ethyl]propane-1,3-diols | NOVARTIS AG (CH) | 2017-07-19 | — | — | EP | disclosed |
| US-9345791-B2 | Ligands for targeting of S1P receptors for in vivo imaging and treatment of diseases | WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER (DE) | 2016-05-24 | — | — | US | disclosed |
| US-9345791-B2 | Ligands for targeting of S1P receptors for in vivo imaging and treatment of diseases | WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER (DE) | 2016-05-24 | — | — | US | disclosed |
| US-9345791-B2 | Ligands for targeting of S1P receptors for in vivo imaging and treatment of diseases | WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER (DE) | 2016-05-24 | — | — | US | disclosed |
| US-9133096-B2 | Process for the production of 2-amino-2[2-(4-C2-20-alkyl-phenyl)ethyl]propane-1,3-diols, and to compounds for use therein | NOVARTIS AG (CH) | 2015-09-15 | — | — | US | disclosed |
| EP-2896609-A1 | Crystalline fingolimod citrate for the treatment of relapsing-remitting multiple sclerosis | ratiopharm GmbH (DE) | 2015-07-22 | — | — | EP | disclosed |
| US-8809571-B2 | Process for the production of 2-amino-2-[2-(4-C2-20-alkyl-phenyl)ethyl]propane-1,3-diols, and to compounds for use therein | NOVARTIS AG (CH) | 2014-08-19 | — | — | US | disclosed |
| WO-2014111949-A1 | INTERMEDIATES AND PROCESS FOR THE PREPARATION OF HIGH PURITY FINGOLIMOD HYDROCHLORIDE | NATCO PHARMA LIMITED (IN) | 2014-07-24 | — | — | WO | disclosed |
| EP-1457478-A2 | Production of 2-amino-2-[2-(4-alkyl-phenyl)ethyl]propane-1,3-diols | Novartis AG (CH) | 2004-09-15 | — | — | EP | disclosed |
| WO-2004010949-A2 | COMPOUNDS ACTIVE IN SPINIGOSINE 1-PHOSPHATE SIGNALING | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2004-02-05 | — | — | WO | disclosed |
| US-20030229251-A1 | Production of 2-amino-2-[2- (4-alkylphenyl) ethyl] propane-1, 3-diols | ABEL STEPHAN (DE) | 2003-12-11 | — | — | US | disclosed |
| US-6605744-B2 | Reducing dialkyl-protected amino-2-(4alkylphenyl)2-oxoalkyl malonate; treating with basic compound and hydrogenating to produce 2-amino-2-(2-(4-C2-20-alkyl-phenyl)ethyl)propane-1,3-diols such as fingolimod | NOVARTIS AG (CH) | 2003-08-12 | — | — | US | disclosed |
| US-20020072635-A1 | Production of 2-amino-2-[2-(4-C2-20-alkyl-phenyl)ethyl]propane-1,3-diols | MITSUI SUGAR CO., LTD. (JP) | 2002-06-13 | — | — | US | disclosed |
| EP-1165563-A1 | BICYCLIC HETEROCYCLES, METHOD FOR PRODUCING THEM AND THEIR USE AS HERBICIDES AND PHARMACEUTICAL AGENTS | Aventis CropScience GmbH (DE) | 2002-01-02 | — | — | EP | disclosed |
| EP-1129066-A1 | PRODUCTION OF 2-AMINO-2- 2-(4-C 2-20?-ALKYL-PHENYL)ETHYL]PROPANE-1,3-DIOLS | Novartis AG (CH) | 2001-09-05 | — | — | EP | disclosed |
| WO-2000056734-A1 | BICYCLIC HETEROCYCLES, METHOD FOR PRODUCING THEM AND THEIR USE AS HERBICIDES AND PHARMACEUTICAL AGENTS | AVENTIS CROPSCIENCE GMBH (DE) | 2000-09-28 | — | — | WO | disclosed |
| WO-2000027798-A1 | PRODUCTION OF 2-AMINO-2-[2-(4-C2-20-ALKYL-PHENYL)ETHYL]PROPANE-1,3-DIOLS | NOVARTIS AG (CH) | 2000-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072635-A1 | Production of 2-amino-2-[2-(4-C2-20-alkyl-phenyl)ethyl]propane-1,3-diols | PLD2, CYP2J2, DECR2 | THRA 3395/4885THRB 3170/4885HAO1 449/4885 |
| US-20030229251-A1 | Production of 2-amino-2-[2- (4-alkylphenyl) ethyl] propane-1, 3-diols | PLD2, CYP2J2, DECR2 | THRA 2915/4885THRB 3065/4885HAO1 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.